In patients with glioblastoma in primary and paired recurrent gliomas, 10 cases (10/11, 90.9%) with SOX2 expression decreased, 1 cases (1/11, 9.1%) were stable (Fig. 2). This evidence concerns the gene SOX2 and central nervous system cancer.